These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4674038)

  • 21. [Symposium; nervous system diseases and metabolism].
    Sobue I; Tsukada Y; Yamada K; Tsubaki T; Wakita T
    Nihon Naika Gakkai Zasshi; 1971 Dec; 60(13):Suppl:24-30. PubMed ID: 4339418
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of nerve growth factor in adrenal autografts in parkinsonism.
    Silani V; Falini A; Strada O; Pizzuti A; Pezzoli G; Motti ED; Vegeto A; Scarlato G
    Ann Neurol; 1990 Mar; 27(3):341-2. PubMed ID: 2327744
    [No Abstract]   [Full Text] [Related]  

  • 23. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

  • 24. [Biochemical aspects of human behaviour (author's transl)].
    Ambrozi L; Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    Folia Clin Int (Barc); 1973 Sep; 23(9):565-87. PubMed ID: 4616856
    [No Abstract]   [Full Text] [Related]  

  • 25. [Catecholamines in the blood of parkinsonism patients].
    Karaban' IN; Ianovich LA; Kudrin VS
    Vrach Delo; 1990 Sep; (9):89-91. PubMed ID: 2284785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Catecholamine metabolism in hypertensive rats.
    Louis WJ; Krauss KR; Kopin IJ; Sjoerdsma A
    Circ Res; 1970 Oct; 27(4):589-94. PubMed ID: 5472848
    [No Abstract]   [Full Text] [Related]  

  • 27. Decreased catecholamines in the adrenal medulla of patients with parkinsonism.
    Carmichael SW; Wilson RJ; Brimijoin WS; Melton LJ; Okazaki H; Yaksh TL; Ahlskog JE; Stoddard SL; Tyce GM
    N Engl J Med; 1988 Jan; 318(4):254. PubMed ID: 3336415
    [No Abstract]   [Full Text] [Related]  

  • 28. [Case of oculocraniosomatic neuromuscular disease associated with parkinsonism with special reference to catecholamine metabolism].
    Sahashi K; Yashima F; Hirose K; Uono M
    Rinsho Shinkeigaku; 1976 Mar; 16(3):235-43. PubMed ID: 987877
    [No Abstract]   [Full Text] [Related]  

  • 29. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL; Rizzo M; Tognoni G
    Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589
    [No Abstract]   [Full Text] [Related]  

  • 30. [Motor and psychomotor activity of striatal monoamines].
    Poirier LJ; Bédard P; Larochelle L
    Laval Med; 1970 Sep; 41(7):894-6. PubMed ID: 4994702
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of thalamotomy on urinary dopamine levels in patients with Parkinsonism.
    Schnieden H; Williams T
    Eur Neurol; 1970; 3(5):290-2. PubMed ID: 5444535
    [No Abstract]   [Full Text] [Related]  

  • 32. [Dopamine and parkinsonism].
    Siegfried J
    Schweiz Med Wochenschr; 1968 Mar; 98(11):429-31. PubMed ID: 5700507
    [No Abstract]   [Full Text] [Related]  

  • 33. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 35. Decreased dopamine and homovanillic acid excretion in a case with chlorpromazine-induced Parkinsonism.
    Messiha FS; Turek I
    Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):329-30. PubMed ID: 4734007
    [No Abstract]   [Full Text] [Related]  

  • 36. Catecholamines.
    Axelrod J; Weinshilboum R
    N Engl J Med; 1972 Aug; 287(5):237-42. PubMed ID: 4402575
    [No Abstract]   [Full Text] [Related]  

  • 37. [Neurochemical basis for pathological motor activity].
    Hole K
    Tidsskr Nor Laegeforen; 1974 Jan; 94(1):11-7. PubMed ID: 4362478
    [No Abstract]   [Full Text] [Related]  

  • 38. Catecholamines in neuropsychiatric states.
    Kety SS
    Pharmacol Rev; 1966 Mar; 18(1):787-98. PubMed ID: 5323770
    [No Abstract]   [Full Text] [Related]  

  • 39. Multipoint analysis of reduced (125)I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine-induced parkinsonism.
    Fukumitsu N; Suzuki M; Fukuda T; Kiyono Y
    Nucl Med Biol; 2009 Aug; 36(6):623-9. PubMed ID: 19647168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Transmethylating activity in vitro in patients with parkinsonism before and after treatment with L-dopa].
    Carella A; Valenti P; Buscaino GA
    Acta Neurol (Napoli); 1971; 26(1):41-5. PubMed ID: 5553940
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.